financetom
Business
financetom
/
Business
/
Wells Fargo earnings climb as investment banking shines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wells Fargo earnings climb as investment banking shines
Jan 15, 2025 4:04 AM

(Reuters) -Wells Fargo's ( WFC ) profit climbed in the fourth quarter, buoyed by stronger investment banking earnings, it said on Wednesday.

The company's shares rose 3.1% to $73.40 in premarket trading.

Wall Street was bolstered by a rebound in activity last year. Increasing confidence spurred companies to issue equity and debt. Corporations also struck deals, lifting volumes from a decade low in 2023.

Bankers expect 2025 to be a much busier year for deals, buoyed by hopes of lower corporate taxes, easing regulations and a broadly pro-business stance under President-elect Donald Trump.

Wells Fargo's ( WFC ) investment banking fees jumped 59% to $725 million in the quarter compared with a year earlier.

The bank advised building materials provider Quikrete on its $11.5 billion deal struck in November to acquire rival Summit Materials and also provided debt financing for the transaction.

The bank was among the lead underwriters on software company ServiceTitan's $718.5 million IPO last month.

Global investment banking revenue jumped 26% to $86.80 billion in 2024, with North America surging 33% compared with a year earlier, according to data from Dealogic.

Wells Fargo ( WFC ) also benefited from easier comparisons with the year earlier, when it took sizeable charges related to severance costs and a special assessment fee it had to pay to refill a government deposit insurance fund.

The fourth-largest U.S. lender's net income rose to $5.08 billion, or $1.43 per share. That compares with $3.45 billion, or 86 cents per share, a year earlier.

REGULATORY FIXES

Under CEO Charlie Scharf's leadership, the bank has undergone a multi-year effort to fix compliance problems from a fake accounts scandal that erupted in 2016.

The U.S. Federal Reserve imposed a $1.95 trillion asset cap in 2018 that prevents Wells Fargo ( WFC ) from growing until regulators deem it has fixed failings in its governance and risk management.

Scharf said last year the asset cap was curtailing the bank's ability to take in more deposits and expand its trading business, two potential growth areas for Wells.

Reuters exclusively reported in November that Wells Fargo ( WFC ) was in the last stages of a process to pass regulatory tests to lift the asset cap that could happen as early as the first half of 2025.

The compliance work has been the bank's top priority for years, with Scharf citing the closing of consent orders as signs of progress.

It still has eight open consent orders, and has closed six since Scharf took the helm in 2019.

The removal of the asset cap would be a major milestone in the bank's years-long effort to repair the damage from the fake accounts scandal and open the window for Wells Fargo ( WFC ) to gain market share.

Scharf last month expressed more confidence in the company's progress.

Wells Fargo's ( WFC ) stock jumped 42.7% in 2024, outperforming rivals JPMorgan ( JPM ), Bank of America, and Citigroup ( C/PN ) as well as the broader KBW Bank index.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
L'Oreal Q1 sales up 9.4% on strong mass market demand
L'Oreal Q1 sales up 9.4% on strong mass market demand
Apr 18, 2024
PARIS (Reuters) -L'Oreal reported a 9.4% rise in first quarter sales on a like-for-like basis on Thursday, beating expectations and shrugging off concerns about a slowdown in leading beauty market the United States. The French cosmetics giant, which owns the Maybelline and Lancome brands, reported sales of 11.24 billion euros ($11.98 billion) for the first three months to the end...
India's Biocon developing its own version of Wegovy, clinical trial likely next year
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Apr 18, 2024
By Rishika Sadam HYDERABAD, April 18 (Reuters) - Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market...
Michigan seeks comment on permit to increase Marathon refinery throughput
Michigan seeks comment on permit to increase Marathon refinery throughput
Apr 18, 2024
April 18 (Reuters) - A Michigan regulator said this week it is seeking public comment on a proposed permit that would allow Marathon Petroleum ( MPC ) to boost crude throughput at its Detroit refinery. Marathon filed an application with the state in March to run its 140,000 barrel per day refinery continuously at full capacity by removing monthly and...
BRIEF-Beyond Enters Into Agreement To Sell Wamsutta Brand & Certain Related Intellectual Property Assets
BRIEF-Beyond Enters Into Agreement To Sell Wamsutta Brand & Certain Related Intellectual Property Assets
Apr 18, 2024
April 18 (Reuters) - Beyond Inc ( BYON ): * BEYOND- ON MARCH 31, ENTERED INTO ASSET PURCHASE AGREEMENT TO SELL WAMSUTTA BRAND & CERTAIN RELATED INTELLECTUAL PROPERTY ASSETS TO INDO COUNT GLOBAL * BEYOND INC ( BYON ) - DEAL FOR $10.25 MILLION IN CASH PLUS ASSUMPTION OF CERTAIN LIABILITIES Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved